Name
GS01-05 - Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: Randomized open-label phase 2 KEYLYNK-009 study (China)
Date & Time
Wednesday, December 20, 2023
Speakers
Virtual Session Link